Instil Bio, Inc. (TIL)

Market Cap	117.99M
Revenue (ttm)	n/a
Net Income (ttm)	-74.14M
Shares Out	6.53M
EPS (ttm)	-11.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,896
Open	19.41
Previous Close	19.36
Day's Range	17.88 - 19.52
52-Week Range	9.62 - 92.00
Beta	1.74
Analysts	Buy
Price Target	114.00 (+530.53%)
Earnings Date	Mar 4, 2025

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It also develops AXN-2510/IMM2510 that is in Phase 1b/2clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. ImmuneOnco is conducting a Phase 1 open label trial in China of AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors that have faile...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 19, 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: TIL
• Website: https://instilbio.com

Analyst Forecast

According to 5 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $114.0, which is an increase of 530.53% from the latest price.

Price Target

$114.0

(530.53% upside)

Analyst Consensus: Buy